Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

NCT01259817 is registered in ClinicalTrials.gov with Ronald Hoffman as lead sponsor.

NCT NCT01259817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01259817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Lead sponsor
Ronald Hoffman
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
December 31, 2016
Enrollment
135 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

high risk essential thrombocythemia, high risk polycythemia vera